Back to top
more

AstraZeneca (AZN)

(Delayed Data from NSDQ)

$77.35 USD

77.35
3,319,830

+0.48 (0.62%)

Updated Oct 11, 2024 04:00 PM ET

After-Market: $77.36 +0.01 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 26% (66 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Sanofi's Dupixent Gets FDA Priority Status for Nasal Polyps

by Zacks Equity Research

Sanofi (SNY) and partner Regeneron's (REGN) Dupixent gets FDA's priority review status for inadequately controlled severe chronic rhinosinusitis with nasal polyps.

The Zacks Analyst Blog Highlights: J&J, Lilly, Pfizer, AstraZeneca and Merck's

by Zacks Equity Research

The Zacks Analyst Blog Highlights: J&J, Lilly, Pfizer, AstraZeneca and Merck's

Should Value Investors Pick AstraZeneca PLC (AZN) Stock?

by Zacks Equity Research

Is AstraZeneca PLC (AZN) a great pick from the value investor's perspective right now? Read on to know more.

Pharma Stock Roundup: FDA OK's J&J Antidepressant, CHMP Recommends Several Drugs

by Zacks Equity Research

J&J's (JNJ) Spravato (esketamine) gets approval for treatment-resistant depression. CHMP recommends approval of several drugs.

J&J's (JNJ) Nasal Spray Spravato Gets FDA Nod for Depression

by Zacks Equity Research

J&J (JNJ) gets FDA nod for its new nasal spray, Spravato (esketamine) for treatment-resistant depression

Mallinckrodt (MNK) Rallies as Earnings Beat Estimates in Q4

by Zacks Equity Research

Mallinckrodt (MNK) tops earnings and sales estimates in the fourth quarter leading to a gain in share price.

Bayer (BAYRY) Q4 Earnings Beat Estimates, Revenues Up Y/Y

by Zacks Equity Research

Bayer's (BAYRY) fourth-quarter 2018 core earnings per share of 31 cents, per American Depositary Receipt ("ADR"), beat the Zacks Consensus Estimate of 26 cents.

Clovis (CLVS) Q4 Earnings Lag Estimates, Rubraca Sales Recover

by Zacks Equity Research

Clovis' (CLVS) top and bottom line miss estimates in the fourth quarter. However, Rubraca sales recover during the quarter.

AstraZeneca/Merck's Lynparza Meets Endpoint in POLO Study

by Zacks Equity Research

AstraZeneca (AZN) and Merck's Lynparza significantly delays disease progression in a late-stage study (POLO) evaluating it as first-line maintenance treatment in pancreatic cancer.

Merck's (MRK) Stock Up Almost 50% in a Year: Here's Why

by Zacks Equity Research

Merck's (MRK) stock is up 45.2% in the past year. Here are reasons for the same.

Strength Seen in AstraZeneca (AZN): Stock Soars 9.3%

by Zacks Equity Research

AstraZeneca (AZN) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

Ironwood (IRWD) Q4 Earnings & Revenues Beat, Shares Rise

by Zacks Equity Research

Ironwood (IRWD) beats on both earnings and sales in the fourth quarter. Shares up.

BMY vs. AZN: Which Stock Is the Better Value Option?

by Zacks Equity Research

BMY vs. AZN: Which Stock Is the Better Value Option?

AstraZeneca's (AZN) Q4 Earnings Beat, New Drugs Drive Sales

by Zacks Equity Research

AstraZeneca (AZN) beats earnings and sales estimates in the fourth quarter and provides encouraging outlook for 2019. Shares up.

Pharma Stock Roundup: Q4 Earnings at MRK, LLY, CHMP Nod for Several Drugs

by Zacks Equity Research

Merck (MRK) and Lilly (LLY) report Q4 results. CHMP gives nod to several drugs.

Alkermes Sinks as FDA Refuses to Approve Depression Drug

by Zacks Equity Research

Alkermes (ALKS) falls almost 5% on a Complete Response Letter from the FDA for its pipeline candidate, ALKS 5461for major depressive disorder (MDD).

Merck (MRK) Beats on Q4 Earnings & Sales as Keytruda Shines

by Zacks Equity Research

Merck (MRK) beats estimates for earnings as well as sales in fourth-quarter 2018. Blockbuster cancer drug, Keytruda continues its robust performance on strong demand trends.

Inovio's Early/Mid-Stage Vaccine Pipeline Exhibits Growth

by Zacks Equity Research

Inovio (INO) focuses on developing its most advanced candidate, VGX-3100 vaccine, which has been advancing well. Reliance on partners for funds to develop its pipeline candidates is a concern.

Merck (MRK) Q4 Earnings Coming Up: What's in the Cards?

by Zacks Equity Research

Merck's (MRK) relatively newer products like Keytruda, Gardasil and Bridion are likely to drive fourth-quarter sales. However, genericization of key drugs and increasing competition are concerns.

Clovis' Rubraca Gets Nod as Maintenance Therapy in Europe

by Zacks Equity Research

Clovis Oncology (CLVS) announces approval of label expansion for Rubraca to include maintenance treatment of ovarian cancer patients in second-line setting in Europe. Shares up.

Sanghamitra Saha headshot

What's Behind the Biotech ETF Rally to Start 2019?

by Sanghamitra Saha

Biotech ETFs have been riding on the wave of mergers and acquisitions as well as drug approvals.

Pharma Stock Roundup: Regulatory Updates in Focus at PFE, BMY, RHHBY, SNY

by Zacks Equity Research

Pfizer's (PFE) tafamidis application gets FDA's priority review. Regulatory updates for Roche's (RHHBY) and Bristol-Myers'(BMY) cancer combination drugs in focus.

Immunomedics Gets CRL From FDA for Breast Cancer Candidate

by Zacks Equity Research

Immunomedics (IMMU) receives a CRL from the FDA pertaining to the BLA for its lead breast cancer candidate, sacituzumab govitecan.

NVS or AZN: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

NVS vs. AZN: Which Stock Is the Better Value Option?

Ironwood's (IRWD) Linzess Gets Approval in China for IBS-C

by Zacks Equity Research

Ironwood Pharmaceuticals (IRWD) gets approval for Linzess in China for the treatment of adults with IBS-C